Prasanna Manjini Sengodan
Interventional Cardiology · Moberly, MONPI 1538561006
Payments from drug & device makers
Across 191 payments — averaging $90.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$3K
- Medtronic$2K
- Philips North America LLC$2K
- Boston Scientific$2K
- W. L. Gore & Associates, Inc.$2K
- Merit Medical Systems Inc$1K
- plus $4K from 24 others
What the payments were for
- Grants$1,1056%
- Travel & lodging$7,79645%
- Food & beverage$7,48343%
- Education$8715%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 25 | $3,115 |
| Medtronic(2 entities) | 25 | $2,494 |
| Philips North America LLC | 15 | $2,347 |
| Boston Scientific | 15 | $2,178 |
| W. L. Gore & Associates, Inc. | 13 | $1,565 |
| Merit Medical Systems Inc | 5 | $1,380 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 15 | $537 |
| Shockwave Medical, Inc | 4 | $522 |
| Abiomed | 6 | $513 |
| E.r. Squibb & Sons, L.L.C. | 23 | $346 |
| Stryker | 5 | $313 |
| Inari Medical, Inc. | 2 | $308 |
| Biotronik Inc. | 3 | $238 |
| Cardiovascular Systems Inc. | 3 | $212 |
| Chiesi USA, Inc. | 3 | $182 |
| Recor Medical Inc | 3 | $167 |
| Terumo Medical Corporation | 4 | $162 |
| AstraZeneca | 4 | $158 |
| Teleflex LLC | 1 | $131 |
| Amgen | 3 | $52 |
| Irhythm Technologies, Inc. | 1 | $49 |
| Sanofi-aventis U.S. LLC | 2 | $46 |
| Surmodics, Inc. | 1 | $41 |
| Acist Medical Systems, Inc. | 1 | $39 |
| Pfizer | 2 | $38 |
| Novartis | 2 | $34 |
| Johnson & Johnson | 2 | $31 |
| Boehringer Ingelheim | 1 | $22 |
| Bayer | 1 | $18 |
| Cordis US CORP. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OPTIS$1,821
- (BQ9) Coronary IVUS$1,576
- GORE CARDIOFORM Septal Occluder$1,129
- GENERAL - STRUCTURAL$1,105
- Prelude IDeal$1,061
- Prelude Sync Distal$1,061
- Advance Needle$1,061
- RESOLUTE ONYX$1,041
- Diamondback Coronary$476
- (BR0) Coronary Atherectomy$369
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$331
- Rad Board$319
- Rad Bd Xtra$319
- Rad Trac$319
- CT THROMBECTOMY SYSTEM KIT$308
- FLOWTRIEVER CATHETER, S$308
- Resolute$289
- Impella$273
- FlowTriever$256
- Rotablator Rotational Atherectomy System Console Kit$250
How this compares
$17,254 in reported general payments places this provider in the 55th percentile of 182 interventional cardiology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 220 | $152,802 |
| EntrestoSacubitril/Valsartan | 140 | $101,313 |
| Repatha SureclickEvolocumab | 83 | $63,108 |
| FarxigaDapagliflozin Propanediol | 59 | $39,162 |
| JardianceEmpagliflozin | 60 | $35,870 |
| XareltoRivaroxaban | 23 | $21,172 |
| Praluent PenAlirocumab | 17 | $8,014 |
| Ranolazine ErRanolazine | 76 | $2,653 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 223 | $2,520 |
| Metoprolol Succinate | 243 | $2,155 |
| Atorvastatin Calcium | 258 | $2,051 |
| Rosuvastatin Calcium | 134 | $1,797 |
| Metoprolol Tartrate | 233 | $1,710 |
| ClopidogrelClopidogrel Bisulfate | 153 | $1,509 |
| Potassium Chloride | 83 | $1,385 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $38 | $152,802220 claims |
| NovartisEntresto | $34 | $101,313140 claims |
| AstraZenecaFarxiga | $158 | $39,16259 claims |
| Boehringer IngelheimJardiance | $22 | $35,87060 claims |
| Johnson & JohnsonXarelto | $31 | $21,17223 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 182 interventional cardiology providers in Missouri.
Other interventional cardiology in Moberly
- Sanjeev RavipudiMoberly$110K
- Harvey SerotaSaint Louis$7.1M
- Adnan ChhatriwallaKansas City$3.6M
- Gil VardiSaint Louis$2M
- Alan ZajariasSaint Louis$1.6M
- James GranthamKansas City$1.6M
- Anish ThomasSaint Louis$1.5M
- Richard BachSaint Louis$1.5M
- Joshua StolkerWashington$1.2M
- John LasalaSaint Louis$995K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.